GAITHERSBURG, Md., USA, September , 2024 — Novavax, Inc. (Nasdaq: NVAX), a pioneer in developing protein-based vaccines, is pleased to announce Dr. Ruxandra Draghia-Akli as the new Executive Vice President and Head of Research & Development, starting November 2024. With over two decades of diverse experience in vaccines and public health, Dr. Draghia-Akli is perfectly poised to lead Novavax’s expanded R&D efforts, focusing on innovative partnerships and addressing critical public health needs.
“Dr. Draghia-Akli’s comprehensive expertise from clinical to policy levels makes her the ideal leader for our R&D endeavors as we enhance our focus on public health solutions,” stated John C. Jacobs, President and CEO of Novavax. “Her vision for scientific strategy will be vital as we aim to expand our technology’s impact beyond our current offerings.”
Previously, Dr. Draghia-Akli has held significant roles including the Global Head of Public Health R&D at Johnson & Johnson, and Vice President of Global Vaccines at Merck. Her work has been instrumental in advancing global health initiatives against some of the most challenging diseases.
Dr. Draghia-Akli expressed her enthusiasm about her new role, “I am thrilled to join Novavax during this transformative phase to lead a dynamic R&D strategy that capitalizes on our unique Matrix-M™ technology to advance public health globally.”
Novavax, Inc. is dedicated to harnessing innovative technologies to enhance global health. Based in Gaithersburg, Maryland, Novavax focuses on creating and commercializing vaccines that prevent serious infectious diseases. Its advanced clinical pipeline includes potential vaccines for COVID-19, influenza, and a combination of both, utilizing its cutting-edge nanoparticle technology and adjuvant systems.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
